Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

Home
/
update
/
details

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

NextEdge Admin

06 Jan 2025

2 min 42 sec

The Abu Dhabi Stem Cells Center (ADSCC) has successfully developed clinical-grade induced pluripotent stem cells (iPSCs) that meet Good Manufacturing Practice (GMP) standards, marking a first in the Middle East. This achievement establishes ADSCC as a leader in regenerative medicine, setting global benchmarks for safety and innovation.

ADSCC scientists developed these iPSCs using a proprietary, virus-free technique that eliminates genetic modifications, reducing the risk of tumor formation and making the cells safer for therapeutic use. iPSCs, derived by reprogramming adult cells into an embryonic-like state, hold immense potential for treating neurodegenerative diseases like Parkinson’s, Alzheimer’s, and multiple sclerosis, as well as diabetes and other conditions. ADSCC is actively researching their applications for personalized medicine.

Professor Yendry Ventura, CEO of ADSCC, emphasized the significance of this milestone, highlighting its potential to transform treatments by offering safer, patient-specific therapies that minimize immune rejection. The center’s research findings will be published in leading medical journals.

Professor Angelo Vescovi, an ADSCC advisor, noted that iPSCs enable the generation of personalized therapeutic cells, such as neural stem cells for brain disorders or pancreatic cells for diabetes. Their virus-free method ensures greater safety and reliability, enhancing clinical application potential.

By establishing an in-house iPSC development protocol, ADSCC strengthens the UAE’s position in global healthcare innovation. With advanced GMP facilities and a highly skilled research team, the center is poised to translate this breakthrough into life-changing therapies. The ability to produce iPSCs locally ensures quality control and accessibility, reducing reliance on external sources.

This achievement reinforces ADSCC’s commitment to advancing stem cell research and personalized medicine, laying the foundation for future breakthroughs that could revolutionize healthcare worldwide.